IL2 and neoplasm: High dose IL-2 therapy was one of the earliest oncologic immunotherapies and it is an effective treatment of metastatic RCC, associated with an objective response in tumour size in over 40% of selected patients and with durable complete remissions in around half of those patients [4,5].